{'fraction_non_alphanumeric': 0.012622720897615708, 'fraction_numerical': 0.0, 'mean_word_length': 5.932038834951456, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The systemic and coronary hemodynamic effects of intracoronary arterial tolazoline (Priscoline).

Intracoronary injection of tolazoline in dogs produces transient coronary vasodilatation with marked reduction in the arteriovenous oxygen difference and little change in myocardial oxygen consumption. At lower doses coronary effects are produced almost exclusively but as the dose increases, systemic cardiovascular changes occur also. No fatalities occurred even with large doses of tolazoline into the coronary arteries of these healthy dogs. Since intraarterial tolazoline is used to improve visualization of vascular beds in other portions of the body, its possible use for coronary arteriography is discussed.